@article{de987584a2284dd1a497f58162ef6215,
title = "Sex influences the accuracy of subjective memory complaint reporting in older adults",
abstract = "Subjective memory complaints (SMC) are required when diagnosing amnestic mild cognitive impairment (aMCI), although their relationship with objective memory performance and Alzheimer's disease (AD) pathology remains unclear. We investigated whether the sex of the patient/participant moderates these associations. Participants were 940 normal control (NC) and aMCI participants from the Alzheimer's Disease Neuroimaging Initiative. SMC were assessed via the memory scale of the Everyday Cognition questionnaire. Discrepancy scores were calculated between self-and informant-reports and categorized into {"}overestimates,{"} {"}comparable estimates{"}, and {"}underestimates{"} of SMC. We conducted linear and logistic regressions to examine the interaction of sex with self-and informant-reported SMC and discrepancy group on the Rey Auditory Verbal Learning Test (RAVLT) Immediate and Delayed Recall and on PET measures of amyloid-β (Aβ) positivity. Diagnosis-stratified analyses were also conducted. Overall, there were sex by self-and informant-reported SMC interactions for Immediate and Delayed Recall. Despite a higher proportion of {"}overestimates{"} in women, greater self-and informantreported SMC showed a stronger relationship to poorer RAVLT scores in women versus men. Diagnosis-stratified analyses revealed that results were driven by aMCI participants. Conversely, overall, greater self-and informant-reported SMC related to greater odds of Aβ positivity regardless of sex. In diagnosis-stratified analyses, only informant-reported SMC related to Aβ positivity in aMCI. Relative to {"}comparable estimates,{"} {"}underestimates{"} of SMC were associated with poorer RAVLT scores across sexes in the overall sample and in aMCI. The predictive utility of self-report SMC may be limited to women in aMCI. Sex differences should be considered when evaluating SMC.",
keywords = "Alzheimer's disease, Amyloid, Awareness, Cognitive reserve, Mild cognitive impairment, Sex differences memory",
author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Sundermann, {Erin E.} and Edmonds, {Emily C.} and Lisa Delano-Wood and Galasko, {Douglas R.} and Salmon, {David P.} and Rubin, {Leah H.} and Bondi, {Mark W.}",
note = "Funding Information: This work was supported by the NIH (grant numbers AG049810, AG05131, and K24 AG026431). Funding Information: This work was supported by the NIH (grant numbers AG049810, AG05131, and K24 AG026431). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) [National Institutes of Health Grant U01AG024904] andDODADNI [Department of Defense award number W81XWH-12-2-0012]. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector con tributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNIdata are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: Data collection and sharing for this project was funded by the Alzheimer{\textquoteright}s Disease Neuroimag-ing Initiative (ADNI) [National Institutes of Health Grant U01 AG024904] and DOD ADNI [Department of Defense award number W81XWH-12-2-0012]. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujire-bio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Neu-roRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector con- Publisher Copyright: {\textcopyright} 2018-IOS Press and the authors. All rights reserved.",
year = "2018",
doi = "10.3233/JAD-170425",
language = "English (US)",
volume = "61",
pages = "1163--1178",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",
}